Research ledger · Source metadata

All new records
229 records available.

The available automated discovery ledger across indexed sources and registries.

Educational boundary. Automatically detected metadata is not a medical conclusion, endorsement, or quality rating. Open the source, examine methods and population, and wait for appropriate review before applying a finding.

Ledger source: Bundled snapshot. Last collected/checked: Sep 16, 2026, 4:43 PM UTC. This ledger may be stale; its timestamp is older than 48 hours or unavailable.

research-article
submitted

5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice.

Europe PMC · 9/15/2026

psilocybinmechanisms

Automated discovery metadata only. Human editorial and qualified review are required before interpreting findings or changing care.

All new records229 records available.

5-HT2A receptor activation is dispensable for psilocybin-induced fear extinction and neuroplasticity in mice.

Implications of Potential US FDA Approval of Psychedelics or Psychedelic-Adjacents Such as Ibogaine for Pharmacy in Japan

Characterizing Psychedelic-Evoked Familiarity: A Comparative Study with Autobiographical and Déjà Vu Experiences.

Therapeutic Alliance and Perceived Closeness in MDMA-Assisted Therapy for Social Anxiety Disorder

MDMA administration reduces ethanol drinking and is associated with altered nociceptin and dynorphin system gene expression in alcohol-preferring rats.

Psilocybin restores spatial memory but not fronto-hippocampal synchrony in a rat model of Alzheimer's disease.

What Is Psilocybin?

Psilocybin.

Psychedelic 4-AcO-DMT attenuated looming-induced freezing behaviors by activating PrL &lt;sup&gt;CaMKIIα&lt;/sup&gt; neurons in mice.

MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis.

A Two-Threshold Model of Psilocybin Response Explains Variability in Psychedelic-Assisted Therapy for Treatment-Resistant Depression

Psilocybin selectively suppresses novelty-induced grooming via 5-HT2B receptors: A microstructure analysis in Wistar rats.

Craving Reduction and Smoking Outcomes in Psilocybin-Assisted and Standard Cessation Care.

Exploratory Insights into 5-MeO-DMT Experiences on Reddit: A Thematic Analysis.

Who Is Reached by Supervised Psilocybin Services? Oregon Services Versus National Psilocybin Use

Higher signal diversity, network dysregulation, and increased well-being under DMT administration: An EEG study.

Psilocybin as an emerging anxiolytic: mechanisms, evidence, and open questions.

No more harm: A guiding principle of psychedelic drug policy

Psychedelic Renaissance: A New Paradigm in Mental Health

A Molecule-Resolved Bibliometric Analysis of PubMed-Indexed Psychedelic Research (2015–2025): Volume, Temporal Trends, and Publication Types

Boundaries or boundlessness? Toward knowledge co-creation in psychedelic-assisted therapy

The therapeutic potential of psychedelic drugs: past, present, and future

MDMA-Assisted Psychotherapy for Cluster B Personality Disorders: A Narrative Review of This Translational Framework for Relational Healing

Exploring Attitudes Toward MDMA-Assisted Therapy in Mental Health Care

One dose of Psilocybin modulates Brain Activity among Depressive patients : Preliminary Neuroimaging Results from the PSILODAC Study

Psilocybin-induced changes in electroencephalography link acute and long-term effects.

Daily briefing: Psilocybin blocks side-effect of chemotherapy in mice.

Long-term maintenance therapy with ketamine infusions for treatment-resistant depression: a retrospective chart review

Electroconvulsive Therapy vs. Ketamine: A Scoping Review and Meta-Analysis of Rapid-Acting Interventions for Acute Suicidality in Adults

Electroconvulsive Therapy and (Es)Ketamine in Treatment-Resistant Depression: A Review of Current Evidence

The use of ketamine in the management of suicidal crisis: a literature review

Longitudinal Assessment of Ketamine-Assisted Community of Practice Therapy: A Retrospective 5-Year Study on Depression, Anxiety and PTSD

Clinical Outcomes of Ketamine Therapy for Depression, Anxiety, and PTSD in Post-TBI Patients

The effect of the Apollo Neuro device on anxiety among participants who underwent ketamine assisted therapy: A non-randomized, observational cohort study

Psilocybin prevents chemotherapy-induced peripheral neuropathy through mitochondrial trafficking preservation.

Effectiveness of IV Ketamine Therapy in the Management of Treatment Resistant Depression

Ketamine Addiction With Multisystem Toxicity: A Case Report From Canon Lan Detox Unit, Neath Port Talbot Hospital, South Wales

Successful Management Of Refractory Precipitated Opioid Withdrawal Syndrome Following Buprenorphine Intake Using Ketamine: A Case Report

Trial of Subcutaneous Ketamine for Psychotic Depression in an Older Adult With Comorbid Physical Illness: A Case Report

A response to the letter to editor: Breaking the chains of depression: A systematic review and meta-analysis of psilocybin therapy.

In Vitro Ketamine Attenuates Immune Sensitization in Major Depressive Disorder in a Concentration-Dependent Manner

515. Influence of the context of administration on 5-MeO-DMT-promoted antidepressant-like effects and neuroplasticity

805. Rapid Antidepressant-Like Effects of 5-MeO-DMT Require Both 5-HT1A and 5-HT2A Receptors

188. A single high-dose acute injection of 5-MeO-DMT reverses stress-induced anhedonia in rats

846. Inconsistent trial risk-of-bias judgements across psychedelic-assisted psychotherapy systematic reviews

252. Clinical application of psychedelic-assisted therapy in major depression and addictions

717. Clinical trials, ethical dimensions, and the pathway of MDMA-assisted therapy in PTSD

530. Detecting neuroplastic effects induced by ketamine and classic psychedelics in healthy human subjects

706. Neurobiology of MDMA and mechanisms in trauma recovery

429. Association between subjective experiences and symptom improvement following psilocybin therapy in Japanese patients with treatment-resistant depression: an open-label study

475. Psilocin pharmacokinetics and exposure-response relationships in Japanese patients with treatment-resistant depression receiving psilocybin therapy: an open-label study

643. A mechanism-informed clinical trial of psilocybin-assisted therapy for opioid use disorder: rationale and neurobiological framework

354. Effects of psilocybin treatment on cognitive function in Japanese patients with treatment-resistant depression: an open-label study

263. Feasibility of psilocybin treatment in Japanese patients with treatment-resistant depression: an open-label study

Psilocybin, From Ancestral Use to Therapeutic Potential: A Multidimensional Review of Its Pharmacological Basis and Current Perspectives.

701. Efficacy and safety of COMP360 psilocybin therapy in anorexia nervosa: a proof-of-concept study

433. Psilocybin reveals diverse antidepressant efficacies across different preclinical models of depression

Factors Associated with Intentions to Use Psilocybin for Mental Health in Relation to Psychotherapy, Psychiatric Medications, and Natural/Synthetic Options.

562. Repeated psilocybin administration does not induce rewarding effects and increases ventral tegmental dopaminergic activity during withdrawal

469. The serotonin 5-HT2A agonist psilocybin in the treatment of neuropathic pain

444. In depth behavioral phenotyping of sex-dependent consequences of maternal separation in mice and effects of psilocybin

Intravenous Infusion of Low Dose Ketamine Versus Dexmedetomedine for Delirium Treatment in Acute Heart Failure

Psychedelic Safety and Clinical Outcomes Across Exposure Patterns: A Structured Narrative Review.

Inhalable Psychedelic 5-MeO-DMT Shows Promise in Treatment-Resistant Depression.

Psychedelics and Ibogaine "Pain Medications" at the Pharmacy Counter: Implications for Pharmacy Practice.

U.S. Psychedelic Use and Microdosing in 2025: Insights from a Probability-Based and Nationally Representative Survey.

Mechanistic insights toward dissociating therapeutic from psychedelic effects: bridging the gap between psychedelic research and mental health care.

Psychedelic-Assisted Interventions in Palliative Care: A Narrative Overview and Critical Evaluation.

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.

Overcoming Pharmacokinetic and Peripheral Safety Challenges in Psychedelic Therapies: The Promise of Advanced Drug Delivery Systems.

Ketamine Gargle for Pain After Pediatric Tonsillectomy

Secular Mysticism: Entanglements of Science and Religion in Psychedelic Medicine.

Psychedelic-Assisted Therapy For Death Acceptance in Terminal Illness: A Scoping Review.

Efficacy of N, N-dimethyltryptamine (DMT) psychedelic therapy for substance misuse: A systematic review and meta-analysis.

Psychedelic-assisted pharmacotherapy: clinical applications and regulatory considerations.

Psychedelic exposure in pregnancy: a scoping review to inform perinatal drug safety and clinical counseling.

Confronting mortality: A meta-analysis and systematic review of psychedelic experiences and death anxiety.

Psychedelic therapy and postpartum depression: priorities and prospects.

Ayahuasca and Its Main Component &lt;i&gt;N,N&lt;/i&gt;-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind.

All new records
229 records available.

Psychedelic 4-AcO-DMT attenuated looming-induced freezing behaviors by activating PrL <sup>CaMKIIα</sup> neurons in mice.

Ayahuasca and Its Main Component <i>N,N</i>-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind.